Increasing numbers of hematopoietic cell transplantations (HCTs) are being performed annually with a greater number of long-term survivors. There is increasing concern regarding the late complications and long-term effects that are secondary to treatment exposures before HCT as well as during the HCT conditioning therapy. In both the autologous as well as allogeneic transplant setting, transplant survivors experience mortality rates higher than the general population and the risk of premature cardiovascular (CV)-related death is increased 2.3-fold compared with the general population. The etiology of CV-related deaths in HCT survivors is multifactorial; however, increasing evidence suggests that HCT survivors are at higher risk of developing adverse CV risk factors leading to the development of the metabolic syndrome (a constellation high triglyceride levels, low high-density lipoprotein-cholesterol, hypertension, high fasting blood sugars and increased waist circumference), which then predisposes individuals to risk for early CV-related death. Resistance to insulin is the primary underlying pathophysiologic mechanism that contributes to the development of metabolic syndrome and HCT survivors have been shown to be more likely to develop hypertension, hyperlipidemia and to be insulin resistant. However, the relationship between HCT-related treatment exposures (total body irradiation, high dose chemotherapy, calcineurin inhibitors, steroids, etc) and transplant-related complications (such as GVHD) with the development of CV risk factors and insulin resistance is still in the early stages of investigation. Greater knowledge of the concern regarding CV risk in HCT survivors among both patients and care providers will provide the opportunity for appropriate screening as well as interventions for modifiable risk factors.
Introduction
Expanding indications and wider eligibility is leading to increased numbers of hematopoietic cell transplantations (HCTs) being performed annually. In conjunction with this, a reduction in the mortality secondary to relapse, infections, GVHD and other acute TRM 1 is improving survival rates and resulting in an ever increasing population of HCT survivors. Whereas most attention has been focused on the acute HCT time period and the associated complications that contribute to early TRM, there is increasing concern regarding the late complications and long-term effects that are secondary to treatment exposures before HCT as well as during the HCT conditioning therapy.
In the autologous as well as the allogeneic transplant setting, transplant survivors experience mortality rates higher than the general population. 2, 3 The Bone Marrow Transplant Survivor Study examined patients who were treated with HCT and had survived for at least 2 years post transplant and found that allogeneic HCT survivors were at a 9.9-fold-increased risk of premature death, and even at 15 years after transplant still were found to have mortality rates twice that of the general population (standardized mortality ratio ¼ 2.2). While relapse of the primary disease and chronic GVHD (cGHVD) were the leading causes of death, late mortality was attributed to treatment-related causes in 25% of deaths and 3% of these were from cardiac-related causes. The risk of premature cardiovascular (CV)-related death was increased 2.3-fold compared with the general population. Similar findings were recently published from the Seattle group where mortality rates in patients who had survived for 45 years after HCT were 4-9-fold higher than the general population for at least 30 years after transplantation. 4 In this analysis, CV-related causes of death were nearly twofold higher than expected (standardized mortality ratio ¼ 1.9). In both of these studies noted above, it is difficult to discern the relative contribution of pre-transplant therapy to the risk of CV-related death, although similar data have been reported in survivors of childhood cancer who have not undergone HCT as part of their therapy where the risk of non-relapse death in patients surviving for X5 years was eightfold higher than the US population and cause-specific mortality for cardiac-related causes was seven times higher. 5 The etiology of CV-related deaths in cancer survivors, including those after HCT, is multifactorial and the studies noted above do not specifically differentiate between anthracycline-associated congestive heart failure, radiation-induced coronary artery disease or other causes that may be disease or treatment related in nature. However, studies of both acute 6 and chronic leukemia survivors 7 after HCT have not found that they are at higher risk of CHF than a sibling comparison group, suggesting that other mechanisms leading to CV risk need to be explored further.
Insulin resistance and CV risk
Metabolic syndrome is a constellation of central obesity, insulin resistance, glucose intolerance, dyslipidemia and hypertension, and is associated with a substantially increased risk for type 2 diabetes mellitus and atherosclerotic CV disease. [8] [9] [10] (Table 1 ) Atherosclerosis is a complex process involving inflammation and cellular proliferation in arterial walls. The development and progression of atherosclerosis is mediated by a variety of growth factors, cytokines, thrombotic factors and vasoactive substances. Insulin resistance is a suspected causal pathway because of its clinical association with increased rates of macrovascular disease and subsequent CV morbidity and mortality. 11 Fasting hyperinsulinemia, a marker of insulin resistance, is associated with atherosclerosis and CV morbidity. 12, 13 Several lines of evidence suggest insulin may directly promote CV pathology: (1) insulin stimulates mitogen-activated protein kinase, mitogenesis and plasminogen activator inhibitor-1 within vascular smooth muscle cells; 14 (2) insulin stimulates endothelin-1 production, with subsequent vascular smooth muscle growth; 15 (3) insulin stimulates ras-p21 in vascular smooth muscle, which promotes increased effects of other growth factors, such as platelet-derived growth factor 16 and (4) the vascular endothelial cell insulin receptor knockout mouse has lower blood pressure and endothelin-1 levels than its wild-type counterpart. 17 In healthy individuals, insulin suppresses hepatic glucose production and promotes the uptake, utilization and storage of glucose by the liver and peripheral tissues. 18 Most peripheral glucose metabolism takes place in muscle (E80%). Insulin resistance is believed by many to have a central role in the pathogenesis of the metabolic syndrome. Differential sensitivity of various tissues to insulin likely has a role in the variability of expression of the metabolic syndrome. Frequently, the liver manifests insulin resistance relative to the periphery; this leads to de novo lipogenesis and dyslipidemia. Hepatic insulin resistance leads to free fatty acid exportation to the muscles to promote muscle insulin resistance. The primary role of hepatic insulin resistance in metabolic syndrome is recapitulated in several animal models. [19] [20] [21] Either impaired hepatic or adipose responses to insulin, or both, can lead to the buildup of circulating free fatty acids, 22 which can lead to a compensatory increase in the secretion of insulin from pancreatic b-cells. 18, 23 Over time, individuals with insulin resistance become hyperinsulinemic. This can take the form of insulin hypersecretion or reduced insulin clearance. 24 As long as the pancreas can adequately compensate for insulin resistance, blood glucose concentrations remain normal; however, in some patients, the capacity of the b-cell erodes over time, 25 which leads to b-cell failure and subsequent type 2 diabetes mellitus.
An independent effect of insulin resistance on CV risk in children has also been suggested. Fasting insulin levels in 6-to 9-year-old children predicted the children's level of blood pressure at age 9-15 years, 26 and in 5-to 9-year-old Pima Indian children, fasting insulin was associated with the level of weight gain during the subsequent 9 years of childhood. 27 The Bogalusa Heart Study has shown a strong relationship over an 8-year period of observation between persistently high fasting insulin levels and the development of CV risk factors in children and young adults. 28 In studies of insulin resistance in childhood that used the euglycemic insulin clamp, an important independent association of both body fat and insulin resistance with increased CV risk factors was shown, as well as an interaction between body fat and insulin resistance, so that the presence of both was associated with a level of CV risk greater than that expected with either body fat or insulin resistance alone. 29 Metabolic syndrome and CV risk after HCT It has been 10-15 years since the first reports, suggesting that insulin resistance may manifest as a consequence of HCT were published. In one study that evaluated patients for metabolic syndrome parameters, 23 long-term survivors (median age 20 years), who were 3-18 years after HCT for hematologic disorders were compared with 13 patients in remission from leukemia without HCT and to 23 healthy 52 and this change has been incorporated into the current definition of metabolic syndrome. 53 age/sex-matched controls. Hyperinsulinemia, impaired glucose tolerance (by oral glucose tolerance test), hypertriglyceridemia, low high-density lipoprotein-cholesterol and abdominal obesity were more common among the HCT patients than among the non-HCT group of leukemia patients or the healthy controls. 30 Core signs of the metabolic syndrome were found in 39% of HCT survivors vs 8% of leukemia controls and 0% of healthy controls. Fifty-two percent of HCT patients were found to have hyperinsulinemia and 43% had abnormal glucose metabolism, compared with none of the healthy controls (P ¼ 0.0002 and 0.001, respectively). Variables associated with hyperinsulinemia in the HCT patients were time from transplantation (P ¼ 0.01), presence of cGVHD (P ¼ 0.01) and hypogonadism (P ¼ 0.04).
Impact of total body irradiation
Another study in 34 children and adolescents after either autologous or allogeneic HCT compared with 21 age/sexmatched controls found that the 18 patients who received TBI had a significantly higher first-phase insulin response and insulinemia/glycemia ratio on glucose tolerance testing as compared with patients who received only lymphoid radiation, no radiation or controls. 31 Thus, suggesting that TBI may have a role in the development of insulin resistance. More recently, a study that compared 48 survivors of conventional therapy for ALL to 26 who underwent HCT with TBI-based conditioning regimens found that at a median age of 15 years, HCT survivors were significantly more likely than non-HCT survivors to manifest multiple adverse cardiac risk factors including central adiposity, hypertension, insulin resistance and dyslipidemia. 32 HCT survivors were significantly more likely to meet the criteria for metabolic syndrome compared with the non-HCT survivors (23.1 vs 4.2%, P ¼ 0.02). In multivariate analyses, history of HCT, any cranial radiation exposure and family history of cardiometabolic disease were all found to be significant risk factors for the presence of two or more abnormal cardiometabolic traits. When individual risk factors were examined, HCT survivors had significantly higher fasting insulin levels and insulin resistance (as measured by the homeostasis model assessment), higher triglyceride levels and lower highdensity lipoprotein-cholesterol levels. Currently, there are no data that examine the potential differential effect of TBI dose on CV risk. The majority, if not all, patients in studies to date have received standard doses of TBI utilized in myeloablative preparative regimens.
Role of growth hormone deficiency
The finding presented above raises the issue of the potential role that growth hormone (GH) deficiency may have in patients who have been exposed to cranial radiation and its impact on the development of adverse CV risk factors, particularly dyslipidemias and insulin resistance. In this study, a history of GH deficiency was not found to be an independent risk factor for increased adverse cardiometabolic traits, although subjects were not prospectively tested for GH deficiency. In another study of metabolic syndrome in adult survivors of childhood ALL who had not undergone HCT but who were all tested for GH deficiency, cranial radiation was strongly associated with GH deficiency and in turn with lower insulin-like growth factor-1, higher fasting insulin levels, abdominal obesity and dyslipidemia. 33 Similar data have also been reported in survivors after HCT who underwent GH stimulation testing and found that 9 of 12 (75%) with metabolic syndrome had insufficient GH response compared with 6/ 19 (31%) with normal GH secretion. 34 Clearly, GH deficiency contributes to the development of adverse CV risk factors in cancer survivors, but this is not the only pathway involved. One of the concerning issues related to all of the studies noted above is that the patients received treatment as children and at the time of assessment they were mostly still adolescents or young adults. The finding of this degree of cardiometabolic derangements in individuals at such young age has significant implications for their risk of premature diabetes and CV disease.
Adult HCT survivors
There is also similar data from adult HCT populations. In one such study, 85 survivors of autologous (n ¼ 46) or allogeneic (n ¼ 39) HCT recipients, who had survived for at least 5 years and had a current median age of 46, were evaluated for features of the metabolic syndrome and compared with age-matched Italian population data. Thirty-four percent of HCT survivors were found to have metabolic syndrome compared with an expected prevalence in the general population of 15% (Po0.0001). Hypertriglyceridemia and low high-density lipoprotein-C were the most common features present. In another report of 86 adults who had allogeneic HCT (median age 50 years, median time after HCT, 3 years) that were compared with 258 age-and gender-matched US population controls from the National Heath and Nutrition Examination Survey database found the prevalence of metabolic syndrome was 49% among HCT recipients, which was a 2.2-fold increase in prevalence compared with population controls. The most common risk factors present were hypertension and hypertriglyceridemia. No patient, donor or transplant characteristics were associated with the diagnosis of metabolic syndrome, although the majority of patients (77%) received TBI.
HCT and CV-related outcomes
The concern over time, as noted above, is that HCT survivors who develop metabolic syndrome will be at higher risk for developing significant CV-related events and/or premature death from CV-related causes. The Bone Marrow Transplant Survivor Study examined diabetes, hypertension and CV events in 1089 patients who were X2-year survivors after HCT. 35 HCT survivors were a mean age of 39.3 years at the time of study survey and the mean follow-up after HCT was 8.6 years. After adjusting for age, sex, race and body mass index (BMI), survivors of allogeneic HCT were 3.6 times more likely to report diabetes than siblings and twice as likely to report hypertension compared with siblings but did not report other CV outcomes with any greater frequency. Allogeneic HCT survivors were also more likely to develop hypertension than autologous recipients. Total body irradiation exposure was associated with an increased risk of diabetes (odds ratio ¼ 3.42; 95% confidence interval ¼ 1.55-7.52). This study demonstrates that HCT survivors have a higher age-and BMI-adjusted risk of diabetes and hypertension, which is of concern as this may potentially lead to a higher than expected risk of CV events as these survivors continue to age.
Rates of CV outcomes also have been examined among nearly 1500 42-year transplant survivors treated at the Fred Hutchinson Cancer Research Program from 1985 to 2006 relative to an age, year and sex-matched populationbased comparison group. 36 Using alternative methodology with state hospital and death registry data defining key CV outcomes, survivors experienced increased CV death (adjusted incidence rate difference per 1000 person-years, 3.6, 95% confidence interval: 1.7, 5.5) and had an increased cumulative incidence of ischemic heart disease, cardiomyopathy/heart failure, stroke, vascular diseases and rhythm disorders. Survivors also had an increased cumulative incidence of related conditions that predispose toward more serious CV disease: hypertension, renal disease, dyslipidemia and diabetes. In this analysis, no consistent differences in hazards were observed following allogeneic compared with autologous HCT aside from an increased rate of hypertension. These data, along with the risk of higher mortality rates in HCT survivors raise significant concerns about how we monitor these survivors on a long-term basis.
Abnormal body composition after HCT
While the association of obesity with diabetes and CV disease risk in the general population is well known, obesity is not a major concern or finding in long survivors after HCT. In fact, data from the Bone Marrow Transplant Survivor Study found that survivors after HCT were no more likely to be obese (as measured by BMI) than a sibling comparison group despite having been exposed to radiation, steroids and prolonged periods of inactivity. 35 However, subsequent studies have revealed that HCT survivors, despite what may be a normal BMI, develop significantly altered body composition that results in both an increase in total PFM (percent fat mass) as well as a reduction in LBM (lean body mass). This finding is termed sarcopenic obesity and results in a loss of myocyte insulin receptors and an increase in adipocyte insulin receptors, the latter of which are less efficient in binding insulin and clearing glucose ultimately contributing to insulin resistance. [37] [38] [39] ( Figure 1 ) We are examining this finding further in an ongoing study of adolescent and adult survivors after myeloablative HCT for hematologic malignancy in childhood. Preliminary data from 119 children and young adults (current mean age 26.1 (±0.8) years, 61.3% male) who had received HCT at a mean age of 12.2 years, ± 0.6) and 81 healthy sibling controls (current mean age 22.8 (±0.9) years, 49.4% male) found that compared with siblings, HCT survivors had significantly lower weight but no differences in BMI or waist circumference. 40 HCT survivors had significantly higher PFM and lower LBM compared with controls. These patients and controls were all assessed for insulin resistance by means of euglycemic hyperinslulinemic clamp studies and HCT survivors were found to be significantly more insulin resistant than their sibling controls and they also had abnormal levels of other CV risk factors (total cholesterol, low-density lipoprotein cholesterol and triglycerides were all significantly higher). Interestingly, these differences were only found in patients who had received total body irradiation as part of their transplant conditioning regimen. These data thus reveal that even at a relatively young age, HCT survivors have increased CV disease risk factors, which are independent of obesity, but may be related to alterations in body composition (kLBM and mPFM), insulin resistance and exposure to TBI. These factors may contribute to a higher risk of early CV disease morbidity and mortality, suggesting that screening and management of modifiable CV disease risk factors should be initiated in HCT survivors.
Monitoring for CV risk after HCT

Surveillance
Guided by existing literature, the US-based Children's Oncology Group has developed screening and surveillance guidelines for childhood cancer survivors based on treatment and host factors. [41] [42] [43] Similar efforts are also occurring in other countries, 44 and efforts are underway to try to harmonize recommendations across countries (M Hudson, personal communication). In addition to recommendations promulgated by oncology groups, other national groups have also produced CV disease screening guidelines specific to children, including defining pediatric sub-populations (including cancer survivors) that are at increased risk of future CV disease 45 (Table 2) . Having cancer survivor-specific recommendations is important given the increased risk of CV and other chronic disease occurring in relatively young adult populations, ages at which many general population-based screening recommendations are not yet applicable. 46 However, in contrast to many general population guidelines, the cost-effectiveness of proposed screening studies and screening intervals has not undergone more rigorous analysis. Given the limited number of older adult survivors of childhood cancer, the applicability of current guidelines for older survivors also is unclear. However, most large cohort studies suggest that the relative risk of CV and other chronic diseases does not plateau and continues to increase compared with control populations. 5, 47, 48 For adult survivors of HCT, the ASBMT has published joint guidelines from the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research and the American Society of Blood and Marrow Transplant Research, 49, 50 which recommends annual CV disease risk factor assessment for both autologous and allogeneic HCT survivors that includes every 5-year assessment for hypertension and hypercholesterolemia (total cholesterol and high-density lipoprotein-cholesterol) starting at age 35 for men and age 45 for women. Diabetes screening is indicated for people with high blood pressure or high cholesterol or for those over age 45 every 3 years. Obviously, these recommendations fail to account for much of the data presented above that clearly indicates that the presence of adverse CV risk factors occur relatively early after HCT and are not dependent upon age making it imperative that screening for these conditions begin early after HCT and continue for the patient's lifetime.
Conclusions
It is clear that HCT survivors have a higher prevalence of CV disease, have CV risk factors present (even at young ages), are more likely to be insulin resistant and more likely to develop diabetes. What has not been studied, however, is whether these risk factors are modifiable with the standard interventions that are utilized for individuals in the general population who may have these same risk factors. Can diet, exercise, treatment of hypertension and hyperlipidemia reduce the risk of CV disease and death in HCT survivors? Should we evaluate HCT survivors more closely for insulin resistance, and would agents that improve insulin resistance be of benefit to these survivors? Clearly routine screening of HCT survivors for CV risk factors should be recommended to our survivors as well as the importance of an ongoing partnership between transplant health-care providers and primary care providers who are best suited to provide survivors with ongoing monitoring and treatment of modifiable CV risk factors. We also need additional research to further delineate the exact pathophysiologic mechanisms leading to insulin resistance, hyperlipidemia and abnormal body composition in HCT survivors that would allow us to be able to determine what parts of HCT treatment are promoting these changes and that could be potentially modified, when do changes start (during HCT and then persist or after HCT) and what can be done in order to prevent the changes in body composition that we are observing. Will the use of reduced intensity conditioning regimens that either significantly reduce the dose or eliminate TBI lead to a lower risk of CV-related outcomes? (Table 3) Ultimately, determining what the modifiable risk factors are will allow us to reduce the risk of late mortality related to CV disease in HCT survivors.
